KisoJi Biotechnology

Heavy-chain-only antibody
#Antibody #Cancer Research UK #KisoJi Biotechnology #Oncology #Phase I trial

First patient receives novel heavy-chain-only antibody

Cancer Research UK and KisoJi Biotechnology have launched a new Phase I/IIa clinical trial for people with selected TROP2-expressing solid tumours.  The study will evaluate the effectiveness and safety of KisoJi’s lead asset, KJ-103, a naked anti-TROP2 antibody.  TROP2 is a transmembrane glycoprotein involved in… Read More

#Cancer Research #News